Pfizer Inc. $PFE Stake Reduced by Birmingham Capital Management Co. Inc. AL

Key Points

• Birmingham Capital Management Co. Inc. AL has reduced its stake in Pfizer Inc. by 6.0%, now owning 163,243 shares worth approximately $4.14 million, making it the 24th largest position in their portfolio.
• Pfizer's recent earnings report showed an EPS of $0.78, surpassing estimates by $0.20, with revenue up 10.3% year-over-year, totaling $14.65 billion.
• Analysts have varied price targets for Pfizer, with the consensus target set at $28.12, while the stock currently has an average rating of "Hold".

Birmingham Capital Management Co. Inc. AL trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 163,243 shares of the biopharmaceutical company's stock after selling 10,344 shares during the period. Pfizer accounts for about 1.6% of Birmingham Capital Management Co. Inc. AL's holdings, making the stock its 24th biggest holding. Birmingham Capital Management Co. Inc. AL's holdings in Pfizer were worth $4,137,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its position in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi lifted its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC acquired a new stake in Pfizer in the first quarter valued at approximately $389,861,000. Starboard Value LP acquired a new stake in Pfizer in the fourth quarter valued at approximately $407,730,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE traded down $0.95 during mid-day trading on Friday, hitting $23.91. The stock had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $135.94 billion, a PE ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. The company's fifty day simple moving average is $24.79 and its two-hundred day simple moving average is $24.30.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer's payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.